Short Interest in Lisata Therapeutics, Inc. (NASDAQ:LSTA) Rises By 59.5%

Lisata Therapeutics, Inc. (NASDAQ:LSTA) was the target of a large growth in short interest during the month of August. As of August 14th, there was short interest totaling 89,867 shares, a growth of 59.5% from the July 30th total of 56,341 shares. Currently, 1.1% of the company’s shares are short sold. Based on an average daily trading volume, of 78,742 shares, the short-interest ratio is presently 1.1 days.

Institutional Investors Weigh In On Lisata Therapeutics

A number of large investors have recently modified their holdings of the company. Bank of America Corp DE purchased a new stake in shares of Lisata Therapeutics during the 2nd quarter worth $35,000. SOL Capital Management CO acquired a new stake in Lisata Therapeutics in the first quarter valued at $61,000. Cerity Partners LLC purchased a new stake in Lisata Therapeutics during the 2nd quarter worth about $32,000. CIBC Bancorp USA Inc. purchased a new stake in Lisata Therapeutics during the 3rd quarter worth about $37,000. Finally, Ground Swell Capital LLC boosted its position in shares of Lisata Therapeutics by 64.0% during the 4th quarter. Ground Swell Capital LLC now owns 38,987 shares of the company’s stock worth $73,000 after acquiring an additional 15,213 shares in the last quarter. 8.94% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

LSTA has been the topic of a number of recent analyst reports. HC Wainwright cut Lisata Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 15th. Weiss Ratings raised Lisata Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. Finally, Zacks Research upgraded Lisata Therapeutics to a “hold” rating in a research note on Monday, May 18th. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Reduce”.

Lisata Therapeutics Stock Performance

LSTA stock traded down $0.20 during mid-day trading on Monday, reaching $1.49. The company had a trading volume of 242,222 shares, compared to its average volume of 182,003. The firm has a fifty day simple moving average of $2.24 and a 200 day simple moving average of $3.40. The company has a market capitalization of $13.43 million, a price-to-earnings ratio of -0.91 and a beta of 0.88. Lisata Therapeutics has a fifty-two week low of $0.99 and a fifty-two week high of $5.07.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.